NBIX closed the week at $135.06, up 5.4% in five sessions, as a clean Q1 earnings release on May 5 triggered a wave of analyst target increases the following morning — a rare show of broad post-results conviction.
The Street response was unusually coordinated. Six firms raised price targets on May 6, all maintaining their existing ratings, signalling that no one felt the need to change their stance but plenty felt the need to move the goalposts higher. Citigroup lifted its target to $246 (from $242), Piper Sandler made the boldest move — up to $207 from $190 — while RBC, Wedbush, and Morgan Stanley also nudged targets upward. Morgan Stanley, still at Equal-Weight, pushed its target to $191 from $185. The consensus sits firmly at Buy, with 18 buy ratings, and the mean price target now at $188.99 — implying roughly 40% upside from the current price. That gap is meaningful. It tells you the Street believes the stock has re-rated through macro noise but hasn't yet priced in the full fundamental story.
The bull case rests on NBIX's dominance in tardive dyskinesia via Ingrezza, supplemented by the addition of Vykat XR for Prader-Willi Syndrome following the Soleno acquisition — a deal bulls argue will be accretive to both revenue and non-GAAP EPS in 2026. Bears counter that the late-stage CNS pipeline carries meaningful trial failure risk, and that without fresh growth levers beyond 2030, today's multiple leaves little room for error. The PE sits at 13.2x and the EV/EBITDA at 10.1x — both relatively compressed for a profitable biotech — which partly explains why the Street's upside targets look so large against the current share price. EPS momentum ranks in the 95th percentile on a 30-day basis, suggesting estimate revisions have been running hard in 's favour ahead of the print.
Short interest, at 5.3% of free float on 5.28 million shares, tells a more textured story than the bullish analyst activity alone would suggest. That level is up roughly 27% on the month — a meaningful build — but the past week saw a modest 2.3% pullback in shares short, consistent with some covering after the earnings beat. The borrow market is not flagging distress. Availability is wide, and the cost to borrow, while nearly doubling over the past month to 0.48% annualised, remains cheap in absolute terms — far from the levels that indicate a crowded or squeezed short base. The ORTEX short score of 41 is firmly in the middle of the range, reinforcing that picture. Shorts that built in April appear to have been positioned for earnings disappointment; some portion has now unwound.
Options positioning has rotated notably since mid-April. The put/call ratio ran above 1.5 for most of April — well into defensive territory — before dropping sharply to around 0.97 in the days immediately following earnings, and ticking back up to 1.01 on May 5. That move from heavy put loading to near-neutral is consistent with earnings hedges being rolled off. The 20-day average PCR of 1.15 still sits above the current reading, so the residual skew is slightly more defensive than the recent tone would imply, but the 52-week range (0.58–1.76) shows current levels are nowhere near extreme in either direction.
Institutional ownership is deep and stable — BlackRock holds 12.8% and Vanguard 9.6%, with JP Morgan Asset Management adding roughly 388,000 shares in the most recently reported period. Insider activity from February was routine: a mix of equity awards and small plan-driven sales at $124, all low-significance. With the stock now 8% above those February transaction prices, no fresh signal there beyond the absence of any notable open-market selling.
The next catalyst to watch is whether the Street's target-upgrade cycle broadens. The Q1 beat has reset the near-term bar; what follows is the quarterly cadence of how Vykat XR's commercial ramp compares to analyst expectations, and whether the CNS pipeline delivers any data readouts that shift the bear case.
See the live data behind this article on ORTEX.
Open NBIX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
